Aims-To assess whether the ability of lipoprotein related variables to discriminate between individuals with or without premature clinical ischaemic heart disease (IHD) was improved using data on high density lipoprotein-lipoprotein AI (HDL-LpAI) fractions, alone or in combination with data on Lp(a). Methods-Lipid and apolipoprotein concentrations were measured in 26 middleaged men (mean age 50 3 years) with early onset IHD and coronary artery bypass grafting prior to sampling, and in 26 matched lipaemic and 26 normolipaemic asymptomatic controls. Results-Triglyceride and Lp(a) concentrations were higher, while HDL cholesterol and apolipoprotein A-I (apoA-I) concentrations were lower in patients than in controls. LpAI concentrations were also lower in IHD patients and were correlated with HDL and apoA-I in both IHD and control groups. Lp(a) was not correlated with any other lipid or apolipoprotein measured in either patients or controls. Univariate discriminant function analysis showed that the proportion correctly classified as patients or controls was marginally greater using LpAI concentrations as the discrimiinator, which was not increased in combination with Lp(a). Serum triglycerides, HDL cholesterol, apoA-I and Lp(a) alone all had similar, but weaker, discriminant power, which increased in various combinations with LpAI. Conclusions-LpAI particle measurement may be useful in research to define mechanisms of cardiovascular protection by HDL but the discriminating power for IHD was only marginally superior to measuring total apoA-I or Lp(a) concentrations. Little further advantage arose through combining LpAI data with other variables. ( Clin Pathol 1995;48:70-74) 
Serum cholesterol is a risk factor for ischaemic heart disease (IHD) from population and group analysis, but has a low predictive power for the development of premature IHD. Other lipid risk factors have been applied in an attempt to improve that correlation. These include low (LDL) and high density lipoprotein (HDL) cholesterol, offering little benefit over total cholesterol,' apolipoprotein A-I (apoA-I),2 apoB,34 both apoA-I and apoB,5 and lipoprotein(a) (Lp(a)).6-8 HDL subfractions of different lipid content and density (HDL2 and HDL3) and of variable apolipoprotein content have also been examined as these various fractions may have different metabolic roles and thus associations with IHD. There are at least two subpopulations of HDL which contain apoA-I: those particles containing apoA-I in association with apoA-II (LpAI:AII) and those containing apoA-I only (LpAI).9 14 These two particles are affected differently by drugs'5 and alcohol,'6 which is consistent with their different metabolic roles and clinical importance. LpAI may act via apoA-I to facilitate cholesterol trafficking between intracellular and plasma membrane pools in the promotion of cholesterol efflux.'7 18 Below-average levels of LpAI particles were reported in patients with established IHD'9 although the association has not been consistently supported in further studies,20 in which concomitant cigarette smoking and use of cardioprotective, antihypertensive or lipid modifying medication with potential effects on HDL were potentially confounding.
A study of middle-aged men after myocardial infarction reported that Lp(a) concentrations were as good as family history at discriminating between patients and controls21; other authors have reported that plasma Lp(a) concentrations above 30 mg/dl are associated with a twofold increase in the risk of premature IHD.22 Lp(a) was also the strongest predictor of angiographically documented IHD in individuals with heterozygous familial hypercholesterolaemia and increased LDL cholesterol concentrations,7 an association supported by some8 but not all later studies. 23 We have studied a group of patients with premature IHD, plus matched controls, to determine whether any differences in apoA-I concentrations were associated with similar differences in LpAI concentrations, and whether LpAI was a better marker of coronary risk than total apoA-I. We have also measured Lp(a) concentrations to see Discriminant value ofLpAI in ischaemic heart disease whether discrimination between those with and without IHD could be improved by measuring Lp(a) in addition to apoA-I and LpAI. Combining LpAI with apoA-I increased the The number of patients and controls in the present study is small, but participant selection and the criteria for matching have advantages with respect to confounding variables, notably smoking and medication. All patients with IHD had undergone coronary angiography and CABG at least six months before sampling and had confirmed disease. Some participants in the control groups may have had significant asymptomatic IHD, and their inclusion would weaken the discriminating power of the lipoprotein variables measured. However, all were asymptomatic, blood pressure had been assessed, some had undergone further cardiovascular assessment including resting electrocardiogram, and the normolipaemic controls completed the exercise programme without developing symptoms of IHD. '7 Comparisons of this nature are the essence of the clinical problem addressed here and for which the assessment of additional laboratory variables could be helpful. LpAI:AII particles were not measured in our study. Reduced concentrations have been reported in hypertriglyceridaemic but not in normotriglyceridaemic patients with angiographically defined coronary artery disease, a discrepancy that may be because of reduced formation of LpAI:AII particles during lipolysis in hypertriglyceridaemic subjects.33 Observations in transgenic animals37 and the identification of human families lacking apoA-II but without premature coronary artery disease38 suggest that apoA-I has a key role in
IHD.
The results obtained here support earlier studies showing that LpAI concentrations are reduced in patients with early onset IHD. This association was also present in the absence of cigarette smoking and cardioprotective, antihypertensive or lipid modulating medication. As in earlier studies, the discriminant power of LpAI strengthened when various other lipoprotein variables were used in combination with LpAI. Discriminant power was not increased by the incorporation of Lp(a), and LpAI alone offered only marginal advantage over the established markers total HDL and apoA-I.
Lipoprotein variables are only one aspect of a range of associations with premature IHD. Subfractions within the HDL particle range are of great interest in research to identify the precise mechanisms by which HDL may exert protective effects against atherosclerosis. At present, as with Lp(a), LpAI measurement should not be used alone or prevail over the range lipid and apolipoprotein tests currently available for assessing individual IHD risk.
